Artal Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Artal Group’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-250,000	Closed	-$11.9M	–	156
2021 Q4	$11.9M	Sell	250,000 -100,000	-29%	-$4.47M	0.32%	64
2021 Q3	$23.3M	Hold	350,000	–	–	0.52%	47
2021 Q2	$27.3M	Buy	350,000 +37,300	+12%	+$2.76M	0.55%	41
2021 Q1	$29.6M	Sell	312,700 -37,300	-11%	-$4.44M	0.52%	44
2020 Q4	$42.6M	Buy	350,000 +25,000	+8%	+$2.74M	0.92%	29
2020 Q3	$28.4M	Sell	325,000 -25,000	-7%	-$1.74M	0.69%	34
2020 Q2	$22.6M	Buy	350,000 +50,000	+17%	+$2.88M	0.63%	40
2020 Q1	$13.4M	Hold	300,000	–	–	0.57%	40
2019 Q4	$18.7M	Sell	300,000 -100,000	-25%	-$4.76M	0.72%	25
2019 Q3	$15M	Buy	400,000 +200,000	+100%	+$8.71M	0.6%	35
2019 Q2	$8.14M	Buy	+200,000	New	+$7.13M	0.33%	59

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Artal Group's TPTX Position: Q1 2022 in Review

Artal Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022, closing a stake of 250,000 shares — an estimated $11.9M sold.

Artal Group first reported a position in TPTX in Q2 2019 and held it in 11 quarters. The position peaked at $42.6M in Q4 2020. 155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

Artal Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Artal Group sold 250,000 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $11.9M.
Artal Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 11 quarters.
Artal Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $42.6M in Q4 2020.
155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Artal Group's 13F filing for Q1 2022, filed 12 May 2022.